Compounded tirzepatide for weight loss

Tirzepatide acts on two metabolic pathways instead of one. Here is how it works, what to expect, and who it is most appropriate for.

What is tirzepatide?

Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It is the active ingredient in Mounjaro and Zepbound. By acting on both pathways, tirzepatide tends to produce greater weight loss than GLP-1-only medications in head-to-head clinical trials.

How does tirzepatide work?

Tirzepatide engages two complementary metabolic systems:

• GLP-1 activity reduces appetite, slows gastric emptying, and improves blood sugar control — the same pathway as semaglutide.
• GIP activity appears to enhance insulin sensitivity, support fat metabolism, and amplify the appetite-reducing effect.

The combination produces a stronger satiety signal at lower nausea levels in many people, which is why average weight loss is typically higher.

Who is tirzepatide for?

Compounded tirzepatide may be appropriate for adults who:

• Have a BMI of 30 or higher, or 27 or higher with weight-related conditions
• Have plateaued or not responded sufficiently to a GLP-1-only medication like semaglutide
• Want a more aggressive weight-loss timeline within a clinical context
• Do not have contraindications (see safety section)

How is tirzepatide dosed?

Dosing is titrated up gradually:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Week 13+: 10 mg, then 12.5 mg, then up to 15 mg as tolerated

Your clinician personalizes titration based on response and tolerability.

Expected results

In the SURMOUNT-1 trial, adults on the 15 mg dose of branded tirzepatide lost an average of 20.9% of body weight at 72 weeks. Many participants achieved ≥25% weight loss. Real-world results depend on dose, consistency, nutrition, and activity.

Common side effects

Side effects are similar to semaglutide and include:

• Nausea, especially during dose increases
• Constipation or diarrhea
• Fatigue, headache, or burping
• Decreased appetite (intended)

Serious but rare risks include pancreatitis, gallbladder issues, kidney problems, and thyroid C-cell tumors. Tirzepatide carries a boxed warning for medullary thyroid carcinoma.

Safety and contraindications

Tirzepatide should not be used by people with a personal or family history of MTC or MEN 2, history of pancreatitis, severe gastrointestinal disease, or during pregnancy and breastfeeding. Your clinician screens for all of these during evaluation.

Frequently asked questions

Related reading

References & sources